RxSight, Inc. (RXST)

RxSight has ample liquidity (about $208.8M cash + short‑term investments at 2026-06-30) and very strong gross margin (~77% TTM), but it remains materially unprofitable (TTM net margin ~-37%, EBITDA margin ~-34%) with ongoing cash burn (TTM free‑cash‑flow yield ~-9.5%). Recent SEC filings and the August 2026 earnings release point to weaker product sales, a withdrawal of 2026 guidance, and an overhang from ongoing securities litigation. EV/Sales around ~2.2× looks reasonable, but earnings-based multiples and DCF outputs are not supportive until profitability improves.

No actionable near-term catalyst is on the tape: the only in-window official PR was a now-passed conference appearance (analyzer: non-material), the Q2 print with the lowered FY2026 standalone guidance and the Alcon collaboration are fully digested 2+ months on, and legal exposure is stale law-firm marketing noise only. The sentiment delta is flat-to-mildly-positive at item level (baseline +0.31 on 15 scored items vs a single +0.3 scored in-window item), retail is silent with zero in-window threads, and the Red-Flag Screen is clean — a quiet-calendar absent setup.

Bearish trend with oversold extremes: price 5.20 sits below every moving average in the suite (SMA20 6.28, SMA50 6.09, SMA200 7.35, EMA9 5.74, EMA21 6.07), MACD line -0.23 below signal -0.05 below zero with the histogram at -0.18 and still expanding negative, and ADX14 17.17 is direction-weak but down. Only the oversold readings (RSI14 31.97, Williams %R -98.68) hint at a possible reflex bounce. Chart quality scores 2 (bounce-only at best) — and the trade is blocked regardless by the qualitative override gate (qualitativeScore 2 < 3), which no chart pattern can override.